Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Impact of the COVID-19 pandemic on tuberculosis management in Spain

  • Aznar, M. L.
  • Espinosa-Pereiro, J.
  • Saborit, N.
  • Jové, N.
  • Sánchez Martinez, F.
  • Pérez-Recio, S.
  • Vitoria, A.
  • Sanjoaquin, I.
  • Gallardo, E.
  • Llenas-García, J.
  • Pomar, V.
  • García, I. O.
  • Cacho, J.
  • Goncalves De Freitas, L.
  • San Martin, J. V.
  • García Rodriguez, J. F.
  • Jiménez-Fuentes, M. Á.
  • De Souza-Galvao, M. L.
  • Tórtola, T.
  • Zules, R.
  • Molina, I.
  • Sánchez-Montalvá, A.
Background: The impact of COVID-19 on the diagnosis and management of tuberculosis (TB) patients is unknown. Methods: Participating centres completed a structured web-based survey regarding changes to TB patient management during the COVID-19 pandemic. The study also included data from participating centres on patients aged ≥18 diagnosed with TB in 2 periods: March 15 to June 30, 2020 and March 15 to June 30, 2019. Clinical variables and information about patient household contacts were retrospectively collected. Results: A total of 7 (70%) TB units reported changes in their usual TB team operations. Across both periods of study, 169 patients were diagnosed with active TB (90 in 2019, 79 in 2020). Patients diagnosed in 2020 showed more frequent bilateral lesions in chest X-ray than patients diagnosed in 2019 (P = 0.004). There was a higher percentage of latent TB infection and active TB among children in households of patients diagnosed in 2020, compared with 2019 (P = 0.001). Conclusions: The COVID-19 pandemic has caused substantial changes in TB care. TB patients diagnosed during the COVID-19 pandemic showed more extended pulmonary forms. The increase in latent TB infection and active TB in children of patient households could reflect increased household transmission due to anti-COVID-19 measures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Association Between Trypanosoma cruzi DNA in Peripheral Blood and Chronic Chagasic Cardiomyopathy, A Systematic Review

  • Bosch-Nicolau, Pau|||0000-0002-7435-1829
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Molina Romero, Israel|||0000-0001-6642-7515
Chronic chagasic cardiomyopathy (CCC) is the most important complication of patients with Chagas disease (CD). The role of persistent detection of DNA in peripheral blood and its association to CCC is unknown. We performed a systematic review up to July 2021, including studies that reported ratios of CCC and PCR positivity among non-treated adult patients. We identified 749 records and selected 12 for inclusion corresponding to 1,686 patients. Eight studies were performed in endemic countries and 4 in non-endemic countries. Only two studies showed an association between CCC and Trypanosoma cruzi parasitemia by means of PCR detection. Six studies reported greater positive PCR ratios among patients with CCC than in the patients with indeterminate chagas disease (ICD) with no statistical significance. A significant risk of bias has been detected among most of the studies. Therefore, while we performed a meta-analysis, wide inter-study heterogeneity impeded its interpretation. Conclusions: With the available information, we could not establish a correlation between PCR-detectable parasitemia and CCC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of Trypanosoma cruzi infection among travellers visiting friends and relatives to continental Latin America

  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Salinas, Catalina|||0000-0002-3600-6434
  • Sullerio, Elena
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Bosch-Nicolau, Pau|||0000-0002-7435-1829
  • Crespillo-Andújar, Clara
  • Trigo, Elena|||0000-0003-4085-7538
  • Roure, Silvia|||0000-0002-7982-0890
  • Valerio, Lluís|||0000-0003-3152-5523
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Molina Romero, Israel|||0000-0001-6642-7515
Chagas disease (CD) is regarded as a possible risk for travellers to endemic areas of continental Latin America (LA). The aim of the study is to determine the risk of Trypanosoma cruzi (TC) infection among travellers to CD endemic areas and to identify risk factors for acquiring TC infection. We designed a multicenter cross-sectional study among travellers in Spain (Badalona, Barcelona and Madrid). All available adults with laboratory confirmed proof of absence of TC infection from January 2012 to December 2015 were contacted. Participants referring a trip to LA after the negative TC screening were offered to participate. We performed a standardized questionnaire of travel related factors and measurement of TC antibodies in serum. A total of 971 participants with baseline negative TC serology were selected from the microbiology records. After excluding participants not meeting inclusion criteria, eighty participants were selected. Sixty three (78.8%) were female, and the median age was 38 (IQR 34-47) years. The reason to travel was visiting friends and relatives in 98.8% of the participants. The median duration of travel was 40 (IQR 30-60) days, with 4911 participants-day of exposure. Seventy seven cases (96.25%) participants had two negative TC serology tests after the travel, two cases (2.5%) had discordant serology results (considered false positive results) and one case was infected before travelling to LA. According to our data, the upper limit of the 95% confidence interval of the incidence rate of TC acquisition in travellers is 0.8 per 1000 participant-days. Among 79 non-CD travellers to TC endemic areas, we found no cases of newly acquired TC infection. The incidence rate of TC acquisition in travellers to endemic countries is less than or equal to 0.8 per 1000 traveller-days. Chagas disease is caused by the protozoan parasite T. cruzi. It is endemic in certain areas of continental Latin America. Few cases of T. cruzi infection have been described in travellers. However, there is little information regarding the incidence rate of T. cruzi infection during a trip to continental Latin America. In this study we aim to study the incidence of T. cruzi infection among migrants from Latin America living in Spain travelling to visit friends and relatives. In this study we found no cases of newly acquired T. cruzi infection among 79 previously uninfected travellers and calculate that the upper limit of the 95% CI of the incidence rate of T. cruzi acquisition in travellers is 0.8 per 1000 participants-day.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Safety of Drugs Used during the First Wave of COVID-19, A Hospital-Registry-Based Study

  • Aguilera, Cristina|||0000-0002-7985-7327
  • Danés Carreras, Immaculada|||0000-0002-8711-9666
  • Guillen Benitez, Elena|||0000-0002-5687-5549
  • Vimes, Alba
  • Bosch Ferrer, Montserrat|||0000-0001-7590-9073
  • Cereza García, Gloria|||0000-0002-0328-100X
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Miarons, Marta|||0000-0001-7847-1580
  • Mestre Torres, Jaume|||0000-0001-6612-221X
  • Agustí Escasany, M. Antònia|||0000-0003-4594-1122
The emergency of the coronavirus disease 2019 (COVID-19) pandemic led to the off-label use of drugs without data on their toxicity profiles in patients with COVID-19, or on their concomitant use. Patients included in the COVID-19 Patient Registry of a tertiary hospital during the first wave were analyzed to evaluate the adverse drug reactions (ADRs) with the selected treatments. Twenty-one percent of patients (197 out of 933) had at least one ADR, with a total of 240 ADRs. Patients with ADRs were more commonly treated with multiple drugs for COVID-19 infection than patients without ADRs (p < 0.001). They were younger (median 62 years vs. 70.1 years; p < 0.001) and took less medication regularly (69.5% vs. 75.7%; p = 0.031). The most frequent ADRs were gastrointestinal (67.1%), hepatobiliary (10.8%), and cardiac disorders (3.3%). Drugs more frequently involved included lopinavir/ritonavir (82.2%), hydroxychloroquine (72.1%), and azithromycin (66.5%). Although most ADRs recovered without sequelae, fatal cases were described, even though the role of the disease could not be completely ruled out. In similar situations, efforts should be made to use the drugs in the context of clinical trials, and to limit off-label use to those drugs with a better benefit/risk profile in specific situations and for patients at high risk of poor disease prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017, A 10-Year Experience

  • Piron, Maria|||0000-0001-6858-9374
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Caballero Requero, Estrella
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Bes, Marta|||0000-0001-6103-072X
  • Casamitjana, Natàlia
  • Puig Sanz, Lluís|||0000-0001-6083-0952
  • Molina Romero, Israel|||0000-0001-6642-7515
  • Sauleda, Silvia|||0000-0001-7343-9557
Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d'Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety.